Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research Article

Therapeutic Use, Efficiency and Safety of the Proteolytic Pineapple Enzyme Bromelain-POS® in Children with Acute Sinusitis in Germany

J.M. BRAUN, B. SCHNEIDER and H.J. BEUTH
In Vivo March 2005, 19 (2) 417-421;
J.M. BRAUN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. SCHNEIDER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.J. BEUTH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Josef.Beuth@medizin.uni-Koeln.de
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The therapeutic efficiency and safety of the proteolytic enzyme bromelaine obtained from pineapple (Bromelain-POS®, Ursapharm GmbH, Saarbrücken, Germany) was evaluated in children under the age of 11 years diagnosed with acute sinusitis. Data from 116 patients from 19 centres located across Germany were analysed in a pharmacoepidemiological cohort study. Patient cohorts were either treated with Bromelain-POS® (N=62), in combination with Bromelain-POS® and standard therapies (N=34), or with standard therapies (N=20). The primary parameter measuring effectiveness of the different treatment groups was the duration of symptoms. The shortest mean period of symptoms was observed in patients treated with Bromelain-POS® alone (6.66 days), followed by the standard therapy (7.95 days) and those treated with a combination of Bromelain-POS® and the standard therapy (9.06 days). Patients of the Bromelain-POS® monotherapy group showed a statistically significant faster recovery from symptoms (p=0.005) compared to the other treatment groups. One 10-year-old male patient, with a known pineapple allergy, showed a self-limiting mild allergic reaction. No other unwanted side-effects were reported. This trial documents that the proteolytic pineapple enzyme Bromelain-POS® is widely used in the treatment of young children diagnosed with acute sinusitis in Germany and that the use of proteolytic enzymes can benefit such patients.

Keywords:
  • Bromelaine
  • acute sinusitis

Footnotes

    • Received October 2, 2004.
    • Accepted December 9, 2004.
  • Copyright © 2005 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

In Vivo: 19 (2)
In Vivo
Vol. 19, Issue 2
March-April 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Use, Efficiency and Safety of the Proteolytic Pineapple Enzyme Bromelain-POS® in Children with Acute Sinusitis in Germany
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Therapeutic Use, Efficiency and Safety of the Proteolytic Pineapple Enzyme Bromelain-POS® in Children with Acute Sinusitis in Germany
J.M. BRAUN, B. SCHNEIDER, H.J. BEUTH
In Vivo Mar 2005, 19 (2) 417-421;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Therapeutic Use, Efficiency and Safety of the Proteolytic Pineapple Enzyme Bromelain-POS® in Children with Acute Sinusitis in Germany
J.M. BRAUN, B. SCHNEIDER, H.J. BEUTH
In Vivo Mar 2005, 19 (2) 417-421;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

In Vivo

© 2023 In Vivo

Powered by HighWire